Biotie And Newron Drop Takeover Plan | Chemical & Engineering News
Volume 89 Issue 45 | p. 13 | Concentrates
Issue Date: November 7, 2011

Biotie And Newron Drop Takeover Plan

Department: Business
Keywords: mergers, Parkinson’s disease

Finland’s Biotie Therapeutics has decided not to ­acquire Newron Pharmaceuticals following Merck KGaA’srecent decision to return to Newron the rights to safinamide, a compound being developed as a Parkinson’s disease treatment. Newron, based in Milan, says it is considering all strategic options for the drug, which is currently in late Phase III clinical trials.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment